These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 30219990)

  • 1. Comparison of
    Palard-Novello X; Beuzit L; Gambarota G; Le Jeune F; Garin E; Salaün PY; Devillers A; Querellou S; Bourguet P; Saint-Jalmes H
    Ann Nucl Med; 2019 Jan; 33(1):47-54. PubMed ID: 30219990
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of choline influx from dynamic
    Palard-Novello X; Blin AL; Bourhis D; Garin E; Salaün PY; Devillers A; Querellou S; Bourguet P; Le Jeune F; Saint-Jalmes H
    Ann Nucl Med; 2018 May; 32(4):281-287. PubMed ID: 29492810
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pairwise comparison of 18F-FDG and 18F-FCH PET/CT in prostate cancer patients with rising PSA and known or suspected second malignancy.
    How Kit N; Dugué AE; Sevin E; Allouache N; Lesaunier F; Joly F; Aide N
    Nucl Med Commun; 2016 Apr; 37(4):348-55. PubMed ID: 26642435
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Usefulness of MRI-assisted metabolic volumetric parameters provided by simultaneous (18)F-fluorocholine PET/MRI for primary prostate cancer characterization.
    Kim YI; Cheon GJ; Paeng JC; Cho JY; Kwak C; Kang KW; Chung JK; Kim EE; Lee DS
    Eur J Nucl Med Mol Imaging; 2015 Jul; 42(8):1247-56. PubMed ID: 25759164
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Voxel-wise correlation of positron emission tomography/computed tomography with multiparametric magnetic resonance imaging and histology of the prostate using a sophisticated registration framework.
    Reynolds HM; Williams S; Jackson P; Mitchell C; Hofman MS; Hicks RJ; Murphy DG; Haworth A
    BJU Int; 2019 Jun; 123(6):1020-1030. PubMed ID: 30536698
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The use of F-18 choline PET in the assessment of bone metastases in prostate cancer: correlation with morphological changes on CT.
    Beheshti M; Vali R; Waldenberger P; Fitz F; Nader M; Hammer J; Loidl W; Pirich C; Fogelman I; Langsteger W
    Mol Imaging Biol; 2009; 11(6):446-54. PubMed ID: 19326171
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of 18F-choline PET/CT in prostate cancer patients with biochemical recurrence: influence of androgen deprivation therapy and correlation with PSA kinetics.
    Beheshti M; Haim S; Zakavi R; Steinmair M; Waldenberger P; Kunit T; Nader M; Langsteger W; Loidl W
    J Nucl Med; 2013 Jun; 54(6):833-40. PubMed ID: 23559588
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The use of F-18 choline PET in the assessment of bone metastases in prostate cancer: correlation with morphological changes on CT.
    Beheshti M; Vali R; Waldenberger P; Fitz F; Nader M; Hammer J; Loidl W; Pirich C; Fogelman I; Langsteger W
    Mol Imaging Biol; 2010; 12(1):98-107. PubMed ID: 19588206
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Value of
    Beheshti M; Taimen P; Kemppainen J; Jambor I; Müller A; Loidl W; Kähkönen E; Käkelä M; Berndt M; Stephens AW; Minn H; Langsteger W
    Eur Radiol; 2023 Jan; 33(1):472-482. PubMed ID: 35864350
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 18F-Fluorocholine PET/CT Complementing the Role of Dynamic Contrast-Enhanced MRI for Providing Comprehensive Diagnostic Workup in Prostate Cancer Patients With Suspected Relapse Following Radical Prostatectomy.
    Vadi SK; Singh B; Basher RK; Watts A; Sood AK; Lal A; Kakkar N; Singh SK
    Clin Nucl Med; 2017 Aug; 42(8):e355-e361. PubMed ID: 28525448
    [TBL] [Abstract][Full Text] [Related]  

  • 11. No clinically relevant differences between positron emission tomography (PET) reconstructions based on low-dose or contrast-enhanced CT in combined integrated multiphase (18) F-Fluorethylcholine PET/CT for prostate cancer.
    Behrendt FF; Lensing C; Keil S; Mottaghy FM; Verburg FA
    J Med Imaging Radiat Oncol; 2016 Aug; 60(4):498-505. PubMed ID: 27297449
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of the Prostate Cancer Bone Metastases: Is It Feasible to Compare 18F-fluorocholine PET/CT, 18F-fluorodeoxyglucose PET/CT and 99mTc-methyl Diphosphonate Bone Scintigraphy?
    Pietrzak AK; Czepczynski R; Wierzchoslawska E; Cholewinski W
    Urol J; 2018 Sep; 15(5):242-247. PubMed ID: 29681049
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [18F]fluoromethylcholine (FCH) positron emission tomography/computed tomography (PET/CT) for lymph node staging of prostate cancer: a prospective study of 210 patients.
    Poulsen MH; Bouchelouche K; Høilund-Carlsen PF; Petersen H; Gerke O; Steffansen SI; Marcussen N; Svolgaard N; Vach W; Geertsen U; Walter S
    BJU Int; 2012 Dec; 110(11):1666-71. PubMed ID: 22520686
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of the PET component of simultaneous [(18)F]choline PET/MRI in prostate cancer: comparison with [(18)F]choline PET/CT.
    Wetter A; Lipponer C; Nensa F; Heusch P; Rübben H; Altenbernd JC; Schlosser T; Bockisch A; Pöppel T; Lauenstein T; Nagarajah J
    Eur J Nucl Med Mol Imaging; 2014 Jan; 41(1):79-88. PubMed ID: 24085502
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnostic value of integrated PET/MRI for detection and localization of prostate cancer: Comparative study of multiparametric MRI and PET/CT.
    Lee MS; Cho JY; Kim SY; Cheon GJ; Moon MH; Oh S; Lee J; Lee S; Woo S; Kim SH
    J Magn Reson Imaging; 2017 Feb; 45(2):597-609. PubMed ID: 27586519
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic value of metabolic parameters and clinical impact of ¹⁸F-fluorocholine PET/CT in biochemical recurrent prostate cancer.
    Colombié M; Campion L; Bailly C; Rusu D; Rousseau T; Mathieu C; Ferrer L; Rousseau N; Kraeber-Bodéré F; Rousseau C
    Eur J Nucl Med Mol Imaging; 2015 Nov; 42(12):1784-93. PubMed ID: 26194716
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recurrent prostate cancer after radical prostatectomy: restaging performance of 18F-choline hybrid PET/MRI.
    Achard V; Lamanna G; Denis A; De Perrot T; Mainta IC; Ratib O; Iselin C; Miralbell R; Garibotto V; Zilli T
    Med Oncol; 2019 Jun; 36(8):67. PubMed ID: 31190232
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison between conventional imaging (abdominal-pelvic computed tomography and bone scan) and [(18)F]choline positron emission tomography/computed tomography imaging for the initial staging of patients with intermediate- tohigh-risk prostate cancer: A retrospective analysis.
    Evangelista L; Cimitan M; Zattoni F; Guttilla A; Zattoni F; Saladini G
    Scand J Urol; 2015; 49(5):345-53. PubMed ID: 25649494
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acquisition with (11)C-choline and (18)F-fluorocholine PET/CT for patients with biochemical recurrence of prostate cancer: a systematic review and meta-analysis.
    von Eyben FE; Kairemo K
    Ann Nucl Med; 2016 Jul; 30(6):385-92. PubMed ID: 27173771
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diffusion-weighted MRI,
    Kitajima K; Yamamoto S; Kawanaka Y; Nakanishi Y; Yamada Y; Go S; Kanematsu A; Kaida H; Yamakado K
    Hell J Nucl Med; 2020; 23(1):34-39. PubMed ID: 32222730
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.